New Medication Given Trump Appears to be For Patients Who Have “Not Mounted Their Own Effective Immune Response”
Doesn’t mean much given the state of regulatory affairs and the FDA. To develop a new drug you basically have to find an open niche that is not currently served, or prove that your drug is better than current therapies. Doesn’t mean the antibody cocktail isn’t effective on patients who do have an immune response. It just means that Regeneron didn’t want to try to compete in the field of other therapeutics because that would mean, in essence, proving that their injection was better on the overall population than other regimens many of which have months of a head start in testing and development.
And given that 95% of people over age 70 (and like 99.x% under 70 years) survive the disease anyway, it’s a very high bar to prove.
Obviously not an emergency to get him to WR. My guess he delayed going till AFTER market closed knowing that and aware such a move would have caused a huge sell off. Man is a great patriot.